Finance

Lists
Why is OSE down 2,12%?
Dive Deeper
OSE:EPA
Ose Immunotherapeutics SA
1,71 €
-2,12%
(-0,037) 1D
6 Õ¶ÕøÕµ, 17:35:26 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for OSE...
Open
1,72 €
High
1,74 €
Low
1,67 €
Mkt. cap
39,53Ā Õ“Õ¬Õ¶
Avg. vol.
177,78Ā Õ°Õ¦Ö€
Volume
98,86Ā Õ°Õ¦Ö€
52-wk high
5,92 €
52-wk low
1,67 €
EPS
-1,69 €
Shares outstanding
23,56Ā Õ“Õ¬Õ¶
No. of employees
64
Open
1,72 €
High
1,74 €
Low
1,67 €
Mkt. cap
39,53Ā Õ“Õ¬Õ¶
Avg. vol.
177,78Ā Õ°Õ¦Ö€
Volume
98,86Ā Õ°Õ¦Ö€
52-wk high
5,92 €
52-wk low
1,67 €
EPS
-1,69 €
Shares outstanding
23,56Ā Õ“Õ¬Õ¶
No. of employees
64
News stories
From web sources and news partners
About Ose Immunotherapeutics SA
CEO-
Employees64
Founded17 Õ¶ÕøÕµ, 2004 Õ©.
Headquarters-
SectorHealth Care
Industry-
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2024 Õ©. Õ½Õ„Õŗ
2024 Õ©. Õ¤Õ„ÕÆ
Revenue
431,00Ā Õ°Õ¦Ö€
431,00Ā Õ°Õ¦Ö€
Cost of goods sold
-
-
Cost of revenue
-
-
Research and development expenses
8,28Ā Õ“Õ¬Õ¶
8,28Ā Õ“Õ¬Õ¶
Total research and development expenses
-
-
Selling, general, and admin expenses
1,08Ā Õ“Õ¬Õ¶
1,08Ā Õ“Õ¬Õ¶
Operating expense
10,22Ā Õ“Õ¬Õ¶
10,22Ā Õ“Õ¬Õ¶
Total operating expenses
10,22Ā Õ“Õ¬Õ¶
10,22Ā Õ“Õ¬Õ¶
Operating income
-9,79Ā Õ“Õ¬Õ¶
-9,79Ā Õ“Õ¬Õ¶
Other non operating income
-611,00Ā Õ°Õ¦Ö€
-611,00Ā Õ°Õ¦Ö€
EBT including unusual items
-10,44Ā Õ“Õ¬Õ¶
-10,44Ā Õ“Õ¬Õ¶
EBT excluding unusual items
-10,53Ā Õ“Õ¬Õ¶
-10,53Ā Õ“Õ¬Õ¶
Income tax expense
-576,50Ā Õ°Õ¦Ö€
-576,50Ā Õ°Õ¦Ö€
Effective tax rate
5,52%
5,52%
Other operating expenses
41,00Ā Õ°Õ¦Ö€
41,00Ā Õ°Õ¦Ö€
Net income
-9,86Ā Õ“Õ¬Õ¶
-9,86Ā Õ“Õ¬Õ¶
Net profit margin
-2Ā 288,86%
-2Ā 288,86%
Earnings per share
-
-
Interest and investment income
571,00Ā Õ°Õ¦Ö€
571,00Ā Õ°Õ¦Ö€
Interest expense
-707,50Ā Õ°Õ¦Ö€
-707,50Ā Õ°Õ¦Ö€
Net interest expenses
-136,50Ā Õ°Õ¦Ö€
-136,50Ā Õ°Õ¦Ö€
Depreciation and amortization charges
-
-
EBITDA
-9,74Ā Õ“Õ¬Õ¶
-9,74Ā Õ“Õ¬Õ¶
Gain or loss from assets sale
-
-
Upcoming events
AI content may include mistakes. Learn more
Google Apps